VolitionRx Expands Nu.Q® Vet Cancer Test Access in U.S. and Asia
Event summary
- VolitionRx has appointed two new centralized laboratory providers for its Nu.Q® Vet Cancer test: Midwest Veterinary Laboratory in the U.S. and Bioguard in Asia.
- Midwest Veterinary Laboratory will offer the test nationwide starting February 2026.
- Bioguard, through its Animal Health Diagnostic Center, becomes the first certified ISO/IEC 17025 animal disease testing laboratory in Taiwan and China to offer the test.
- The Total Addressable Market for Canine Screening is approximately $100 million for the U.S., Europe, and Japan, increasing to nearly $150 million with the addition of China.
The big picture
VolitionRx's expansion of its Nu.Q® Vet Cancer Test access aligns with the growing trend of early disease detection in veterinary medicine. The strategic partnerships with Midwest Veterinary Laboratory and Bioguard position VolitionRx to capture a significant share of the $150 million Total Addressable Market. This move underscores the company's focus on leveraging epigenetics for early cancer detection, a rapidly evolving field with substantial market potential.
What we're watching
- Market Penetration
- How quickly the Nu.Q® Vet Cancer Test will be adopted by veterinarians and pet owners in the U.S. and Asia.
- Revenue Growth
- Whether the expanded access will translate into significant revenue growth for VolitionRx.
- Competitive Dynamics
- The pace at which competitors may enter the canine cancer early detection market.
Related topics